Alnylam Pharmaceuticals (ALNY) Reports Promising Phase 1b Results for Huntington's Disease Therapy

gurufocus.com · 2026-10-23

On October 23, 2026, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced encouraging data from its Phase 1b clinical trial of brezosiran (ALN-HTT02), an invest

Read the full story at gurufocus.com →